Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 25;160(1):287–301.e20. doi: 10.1053/j.gastro.2020.09.029

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the AGA Institute.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Supplementary Figure 6 — The effect of ustekinumab (CERTIFI cohort) on ACE2 and TMPRSS2 gene expression in the intestine. (A) Baseline differences in expression of ACE2 and TMPRSS2 between inflamed and noninflamed tissue was estimated across different regions (ileum, colon, and rectum) using a mixed-effect model with tissue and region and its interactions as fixed effects and random intercepts for each patient. P values indicated the significance of the inflamed vs noninflamed comparison. (B) Changes in gut expression of ACE2 (top) and TMPRSS2 (bottom) in patients with CD treated with ustekinumab (CERTIFI cohort). Treatment changes in expression of ACE2 and TMPRSS2 were modeled using a mixed-effect model with visit, region, tissue, and treatment and its interactions as fixed effects. Marginal estimated means are presented for patients treated with ustekinumab and placebo group at baseline and week 6 across different gut regions. P values denote significance of change at week 6 from screening, +P < . 1, ∗P < . 05. (C) As no change was observed in noninflamed biopsies, treatment effect on inflamed biopsies was compared between week 22 clinical responders and nonresponders vs baseline. +P < . 1, ∗P < . 05. The samples sizes are summarized in Supplementary Table 6.